Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.35 |
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | CDC25A | P30304 | 5/20 | 0.31 |
| ▸ | CDC25B | P30305 | 5/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.31 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | ALB | P02768 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | RARB | P10826 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL364135 | 0.78 | — | — | |
| SCHEMBL9482405 | 0.75 | — | — | |
| SCHEMBL364738 | 0.74 | ALOX5 (0.41) | PTGS2ALOX5HMGCRPRKCAPLA2G2A | |
| SCHEMBL9812598 | 0.74 | — | — | |
| SCHEMBL9038940 | 0.72 | NFE2L2 (0.39) | — | |
| SCHEMBL24381615 | 0.71 | APEX1 (0.34) | PTGS2ALOX5HMGCR | |
| SCHEMBL2225565 | 0.69 | CDC25A (0.35) | CDC25ACDC25B | |
| SCHEMBL9343868 | 0.69 | THRB (0.34) | PTGS2ALOX5HMGCR | |
| SCHEMBL7363051 | 0.69 | ALOX5 (0.38) | PTGS2ALOX5HMGCRPRKCAPLA2G2A | |
| SCHEMBL1665531 | 0.69 | ALOX5 (0.33) | PTGS2ALOX5HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677632-A | A method for preparing 5-hydroxy-4 isobutyl-2,5 dihydrofuran 2-one | 珠海润都制药股份有限公司 | 2023-02-03 | — | — | CN | claimed |
| WO-2008127646-A2 | TRANSAMINASE-BASED PROCESSES FOR PREPARATION OF PREGABALIN | DSM IP ASSETS B.V. (NL) | 2008-10-23 | — | — | WO | claimed |
| CN-115677632-A | A method for preparing 5-hydroxy-4 isobutyl-2,5 dihydrofuran 2-one | 珠海润都制药股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115677632-A | A method for preparing 5-hydroxy-4 isobutyl-2,5 dihydrofuran 2-one | 珠海润都制药股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115677632-A | A method for preparing 5-hydroxy-4 isobutyl-2,5 dihydrofuran 2-one | 珠海润都制药股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-3216863-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PREGABALIN | PFIZER IRELAND PHARMACEUTICALS (IE) | 2017-09-13 | — | — | EP | disclosed |
| EP-2978748-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PREGABALIN | PFIZER IRELAND PHARMACEUTICALS (IE) | 2017-05-10 | — | — | EP | disclosed |
| US-20160024540-A1 | Process and Intermediates for the Preparation of Pregabalin | PFIZER INC | 2016-01-28 | — | — | US | disclosed |
| US-20160024540-A1 | Process and Intermediates for the Preparation of Pregabalin | PFIZER INC | 2016-01-28 | — | — | US | disclosed |
| WO-2014155291-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PREGABALIN | PFIZER IRELAND PHARMACEUTICALS (IE) | 2014-10-02 | — | — | WO | disclosed |
| US-8716520-B2 | Method of resolution of (RS)- 1,1′-BI-2-naphthol for obtaining enantiomeric pure I.E. (S)-(−)-1,1′-BI-2-naphthol and/or (R)-(+)-1,1′-BI-2-naphthol via co-crystal formation with optically active derivatives of γ-amino acids | LUPIN LIMITED (IN) | 2014-05-06 | — | — | US | disclosed |
| US-8716520-B2 | Method of resolution of (RS)- 1,1′-BI-2-naphthol for obtaining enantiomeric pure I.E. (S)-(−)-1,1′-BI-2-naphthol and/or (R)-(+)-1,1′-BI-2-naphthol via co-crystal formation with optically active derivatives of γ-amino acids | LUPIN LIMITED (IN) | 2014-05-06 | — | — | US | disclosed |
| US-20120316361-A1 | METHOD OF RESOLUTION OF (RS)- 1,1'-BI-2-NAPHTHOL FOR OBTAINING ENANTIOMERIC PURE I.E. (S)-(-)-1,1'-BI-2-NAPHTHOL AND/OR (R)-(+)-1,1'-BI-2-NAPHTHOL VIA CO-CRYSTAL FORMATION WITH OPTICALLY ACTIVE DERIVATIVES OF y -AMINO ACIDS | LUPIN LIMITED (IN) | 2012-12-13 | — | — | US | disclosed |
| US-20120316361-A1 | METHOD OF RESOLUTION OF (RS)- 1,1'-BI-2-NAPHTHOL FOR OBTAINING ENANTIOMERIC PURE I.E. (S)-(-)-1,1'-BI-2-NAPHTHOL AND/OR (R)-(+)-1,1'-BI-2-NAPHTHOL VIA CO-CRYSTAL FORMATION WITH OPTICALLY ACTIVE DERIVATIVES OF y -AMINO ACIDS | LUPIN LIMITED (IN) | 2012-12-13 | — | — | US | disclosed |
| WO-2012007814-A2 | THREE COMPONENT CO-CRYSTAL FORMATION BETWEEN DIASTEREOMERIC MIXTURES OF 3-ALKYL-4-((S)-1'PHENYLETHYLAMINO) BUTANOIC ACID AND OPTICALLY PURE 1, 1'-BI-2-NAPHTHOL | LUPIN LIMITED (IN) | 2012-01-19 | — | — | WO | disclosed |
| WO-2011086565-A1 | METHOD FOR PREPARATION OF ENANTIOMERICALLY ENRICHED AND/OR RACEMIC GAMMA-AMINO ACIDS | LUPIN LIMITED (IN) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011086565-A1 | METHOD FOR PREPARATION OF ENANTIOMERICALLY ENRICHED AND/OR RACEMIC GAMMA-AMINO ACIDS | LUPIN LIMITED (IN) | 2011-07-21 | — | — | WO | disclosed |
| WO-2008127646-A2 | TRANSAMINASE-BASED PROCESSES FOR PREPARATION OF PREGABALIN | DSM IP ASSETS B.V. (NL) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008127646-A2 | TRANSAMINASE-BASED PROCESSES FOR PREPARATION OF PREGABALIN | DSM IP ASSETS B.V. (NL) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024540-A1 | Process and Intermediates for the Preparation of Pregabalin | GABRE, GABRG1, GABRG2 | PTGS2 401/4885ALOX5 1545/4885HMGCR 207/4885 |
| US-20120316361-A1 | METHOD OF RESOLUTION OF (RS)- 1,1'-BI-2-NAPHTHOL FOR OBTAINING ENANTIOMERIC PURE I.E. (S)-(-)-1,1'-BI-2-NAPHTHOL AND/OR (R)-(+)-1,1'-BI-2-NAPHTHOL VIA CO-CRYSTAL FORMATION WITH OPTICALLY ACTIVE DERIVATIVES OF y -AMINO ACIDS | RRS1, RER1, QTRT1 | PTGS2 3356/4885ALOX5 1787/4885HMGCR 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.